Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer’s disease

Ghosh Shampa; Sachdeva Bhuvi; Sachdeva Punya; Chaudhary Vishal; Rani Gokana Mohana; Sinha Jitendra Kumar

doi:10.1007/s42823-022-00397-9

Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer’s disease

Carbon Letters
Abbr : Carbon Lett.
2022, 32(6), pp.1381-1394
DOI : 10.1007/s42823-022-00397-9
Publisher : Korean Carbon Society
Research Area : Natural Science > Natural Science General > Other Natural Sciences General
Received : July 23, 2022
Accepted : August 27, 2022
Published : October 1, 2022

Ghosh Shampa ¹, Sachdeva Bhuvi ², Sachdeva Punya ³, Chaudhary Vishal ², Rani Gokana Mohana ⁴, Sinha Jitendra Kumar ³

¹ICMR—National Institute of Nutrition, Tarnaka, Hyderabad
²Research Cell and Department of Physics, Bhagini Nivedita College, University of Delhi, Delhi
³GloNeuro, Sector 107, Vishwakarma Road, Noida
⁴Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Keelung Road, Taipei, 10607, Taiwan, ROC

Accredited

ABSTRACT

Alzheimer's disease (AD) is one of the most common forms of dementia, affecting more than 50 million people globally. The onset of AD is linked to age, smoking, obesity, hypercholesterolemia, physical inactivity, depression, gender, and genetics of an individual. The accumulation of Aβ peptides and neurofibrillary tangles (NFTs) in the brain is one of the critical factors that lead to AD, which is known to disrupt neuronal signaling and causing neurodegeneration. As per the current understanding, inhibiting the accumulation of Aβ peptides and NFTs is crucial in the management/treatment of AD. Latest research studies show that nanoparticles have the potency of improving drug transport across the blood–brain barrier easily. Specifically, graphene quantum dots (GQDs), a type of semiconducting nanoparticles, have been established as effective inhibitors for blocking the aggregation of Aβ peptides. The small size of GQDs allows them to pass through the blood–brain barrier with ease. Moreover, GQDs have fluorescence properties, which can be used to detect the concentration of Aβ in vivo. In recent years, compared to other carbon materials, the low cytotoxicity and high biocompatibility of GQDs, give them an advantage in the suitability and clinical research for AD. In this manuscript, we have discussed the role of different types of nanoparticles in the transportation of encapsulated or co-assembled compound drugs for the treatment of AD and importantly, the role of GQDs in the diagnosis and management/treatment of AD.

KEYWORDS

Blood–Brain barrier, Liposomes, Curcumin, Quercetin, Aβ peptides neurotherapeutics, Nanotheranostics

Citation status

This is the result of checking the information with the same ISSN, publication year, volume, and start page between the WoS and the KCI journals. (as of 2024-07-26)

Total Citation Counts(KCI+WOS) (24) This is the number of times that the duplicate count has been removed by comparing the citation list of WoS and KCI.

Scopus Citation Counts (36) This is the result of checking the information with the same ISSN, publication year, volume, and start page between articles in KCI and the SCOPUS journals. (as of 2024-10-01)

* References for papers published after 2023 are currently being built.

[journal] Ghosh S / 2020 / Current status of drug targets and emerging therapeutic strategies in the management of Alzheimer’s disease / Curr Neuropharmacol 18(9) : 883~903

[journal] Crous-Bou M / 2017 / Alzheimer’s disease prevention : from risk factors to early intervention / Alzheimer’s Res Therapy 9(1) : 71~

[journal] Möller HJ / 1998 / The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections / Eur Arch Psychiatry Clin Neurosci 248(3) : 111~122

[journal] Jack CR Jr / 2008 / The Alzheimer’s disease neuroimaging initiative(ADNI) : MRI methods / J Magn Resonan Imaging JMRI 27(4) : 685~691

[journal] Sperling RA / 2011 / Toward defining the preclinical stages of Alzheimer’s disease : recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease / Alzheimer’s Dement 7(3) : 280~292

[journal] Pollock NJ / 1986 / Filamentous aggregates in Pick’s disease, progressive supranuclear palsy, and Alzheimer’s disease share antigenic determinants with microtubule-associated protein, tau / Lancet (Lond, Engl) 2(8517) : 1211~

[journal] Montine TJ / 2012 / National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease : a practical approach / Acta Neuropathol 123(1) : 1~11

[journal] Mishra P / 2021 / SIRT1 promotes neuronal fortification in neurodegenerative diseases through attenuation of pathological hallmarks and enhancement of cellular lifespan / Curr Neuropharmacol 19(7) : 1019~1037

[journal] Ghosh S / 2019 / “Obesageing”: linking obesity & ageing / Indian J Med Res 149(5) : 610~615

[journal] DeKosky ST / 2003 / Looking backward to move forward : early detection of neurodegenerative disorders / Science 302(5646) : 830~834

[journal] Mantzavinos V / 2017 / Biomarkers for Alzheimer’s disease diagnosis / Curr Alzheimer Res 14(11) : 1149~1154

[journal] Ghosh S / 2016 / Epigenomic maintenance through dietary intervention can facilitate DNA repair process to slow down the progress of premature aging / IUBMB Life 68(9) : 717~721

[journal] Ghosh S / 2021 / Role of phytomolecules in the treatment of obesity : targets, mechanisms and limitations / Curr Top Med Chem 21(10) : 863~877

[journal] Thal LJ / 2005 / A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment / Neuropsychopharmacology 30(6) : 1204~1215

[journal] Rogers J / 1993 / Clinical trial of indomethacin in Alzheimer’s disease / Neurology 43(8) : 1609~1611

[journal] Scharf S / 1999 / A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease / Neurology 53(1) : 197~201

[journal] Aisen PS / 2003 / Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression : a randomized controlled trial / JAMA 289(21) : 2819~2826

[journal] Thatte U / 2005 / Phenserine axonyx / Curr Opin Investig Drugs 6(7) : 729~739

[journal] Wang C / 2019 / The relationship between cholesterol level and Alzheimer’s diseaseassociated APP proteolysis/Aβ metabolism / Nutr Neurosci 22(7) : 453~463

[journal] Fillit H / 2010 / Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer’s disease who are taking donepezil / Evid Based Ment Health 13(4) : 117~

[journal] Greenberg SM / 2006 / A phase 2 study of tramiprosate for cerebral amyloid angiopathy / Alzheimer Dis Assoc Disord 20(4) : 269~274

[journal] Gauthier S / 2009 / Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease : exploratory analyses of the MRI sub-group of the Alphase study / J Nutr Health Aging 13(6) : 550~557

[journal] Labie C / 2006 / Effects of paliroden(SR57667B)and xaliproden on adult brain neurogenesis / Curr Alzheimer Res 3(1) : 35~36

[journal] Ramassamy C / 2007 / Ginkgo biloba extract(EGb 761)in Alzheimer’s disease : is there any evidence? / Curr Alzheimer Res 4(3) : 253~262

[journal] DeKosky ST / 2008 / Ginkgo biloba for prevention of dementia : a randomized controlled trial / JAMA 300(19) : 2253~2262

[journal] Bassil N / 2010 / Memantine ER, a once-daily formulation for the treatment of Alzheimer’s disease / Expert Opin Pharmacother 11(10) : 1765~1771

[journal] Brambilla D / 2017 / Drug discovery, development and delivery in Alzheimer’s disease / Pharm Res 35(1) : 3~

[journal] De Jong WH / 2008 / Drug delivery and nanoparticles : applications and hazards / Int J Nanomed 3(2) : 133~149

[journal] Yohan D / 2014 / Applications of nanoparticles in nanomedicine / J Biomed Nanotechnol 10(9) : 2371~2392

[journal] Fan Y / 2021 / Analytical characterization of liposomes and other lipid nanoparticles for drug delivery / J Pharm Biomed Anal 192 : 113642~

[journal] Narendra MAK / 2020 / Formulation and in vitro evaluation of upconversion nanoparticle-loaded liposomes for brain cancer / Ther Deliv 11(9) : 557~571

[journal] Poovaiah N / 2018 / Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers / Nanoscale 10(36) : 16962~16983

[journal] Gastaldi L / 2014 / Solid lipid nanoparticles as vehicles of drugs to the brain : current state of the art / Eur J Pharmac Biopharmac 87(3) : 433~444

[journal] Rahiminejad A / 2019 / Preparation and investigation of indirubin-loaded SLN nanoparticles and their anti-cancer effects on human glioblastoma U87MG cells / Cell Biol Int 43(1) : 2~11

[journal] Costa C / 2019 / Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis / J Control Rel 295 : 187~200

[journal] Morsi NM / 2013 / Brain targeted solid lipid nanoparticles for brain ischemia : preparation and in vitro characterization / Pharm Dev Technol 18(3) : 736~744

[journal] Li JC / 2015 / Preparation and brain delivery of nasal solid lipid nanoparticles of quetiapine fumarate in situ gel in rat model of schizophrenia / Int J Clin Exp Med 8(10) : 17590~17600

[journal] Uppuluri CT / 2021 / Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson’s disease / Int J Pharm 606 : 120881~

[journal] Patel T / 2012 / Polymeric nanoparticles for drug delivery to the central nervous system / Adv Drug Deliv Rev 64(7) : 701~705

[journal] Elzoghby AO / 2016 / Natural polymeric nanoparticles for brain-targeting : implications on drug and gene delivery / Curr Pharm Des 22(22) : 3305~3323

[journal] Sousa F / 2010 / Functionalized gold nanoparticles : a detailed in vivo multimodal microscopic brain distribution study / Nanoscale 2(12) : 2826~2834

[journal] Moghimi SM / 2003 / Stealth liposomes and long circulating nanoparticles : critical issues in pharmacokinetics, opsonization and protein-binding properties / Prog Lipid Res 42(6) : 463~478

[journal] Masserini M / 2013 / Nanoparticles for brain drug delivery / ISRN biochemistry 2013 : 238428~

[journal] Weiss N / 2009 / The bloodbrain barrier in brain homeostasis and neurological diseases / Biochem Biophys Acta 1788(4) : 842~857

[journal] Wang XY / 2015 / The permeability and transport mechanism of graphene quantum dots(GQDs)across the biological barrier / Nanoscale 7(5) : 2034~2041

[journal] Abbott NJ / 2010 / Structure and function of the blood-brain barrier / Neurobiol Dis 37(1) : 13~25

[journal] Li S / 2016 / Crossing the blood-brain-barrier with transferrin conjugated carbon dots : a zebrafish model study / Colloids Surf B Biointerfaces 145 : 251~256

[journal] Sahu JK / 2018 / Tools in the design of therapeutic drugs for cns disorders : an up-to-date review / Curr Mol Pharmacol 11(4) : 270~278

[journal] Saraiva C / 2016 / Nanoparticle-mediated brain drug delivery : overcoming blood-brain barrier to treat neurodegenerative diseases / J Control Rel 235 : 34~47

[journal] Chaudhary V / 2015 / Solitary surfactant assisted morphology dependent chemiresistive polyaniline sensors for room temperature monitoring of low parts per million sulfur dioxide / Polym Int 64 : 1475~1481

[journal] Cho K / 2008 / Therapeutic nanoparticles for drug delivery in cancer / Clin Cancer Res 14(5) : 1310~1316

[journal] Gilleron J / 2013 / Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape / Nat Biotechnol 31(7) : 638~646

[journal] Liu Z / 2013 / B6 peptidemodified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide / Bioconjug Chem 24(6) : 997~1007

[journal] Kurakhmaeva KB / 2009 / Brain targeting of nerve growth factor using poly(butyl cyanoacrylate)nanoparticles / J Drug Target 17(8) : 564~574

[journal] Kulkarni PV / 2010 / Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease / Wiley Interdiscip Rev Nanomed Nanobiotechnol 2(1) : 35~47

[journal] Xie J / 2010 / Nanoparticle-based theranostic agents / Adv Drug Deliv Rev 62(11) : 1064~1079

[journal] Pinheiro R / 2020 / Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer’s disease / Eur J Pharmac Sci 148 : 105314~

[journal] Manek E / 2020 / Use of biodegradable, chitosan-based nanoparticles in the treatment of Alzheimer’s disease / Molecules (Basel, Switzerland) 25(20) : 4866~

[journal] Loureiro JA / 2017 / Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease / Molecules (Basel, Switzerland) 22(2) : 277~

[journal] Gao F / 2020 / Preparation and in vitro evaluation of multi-targetdirected selenium-chondroitin sulfate nanoparticles in protecting against the Alzheimer’s disease / Int J Biol Macromol 142 : 265~276

[journal] Zhang J / 2021 / Neuroprotective effects of maize tetrapeptide-anchored gold nanoparticles in Alzheimer’s disease / Colloids Surf B Biointerfaces 200 : 111584~

[journal] Sanati M / 2019 / Impact of gold nanoparticles on amyloid β-induced Alzheimer’s disease in a rat animal model : involvement of STIM proteins / ACS Chem Neurosci 10(5) : 2299~2309

[journal] Liu Y / 2019 / Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer’s disease / J Colloid Interface Sci 552 : 388~400

[journal] Wang W / 2021 / Coassembled chitosan-hyaluronic acid nanoparticles as a theranostic agent targeting Alzheimer’s β-amyloid / ACS Appl Mater Interfaces 13(47) : 55879~55889

[journal] El-Ganainy SO / 2021 / Galantamine nanoparticles outperform oral galantamine in an Alzheimer’s rat model: pharmacokinetics and pharmacodynamics / Nanomedicine (Lond) 16(15) : 1281~1296

[journal] Kwon HJ / 2016 / Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer’s disease / ACS Nano 10(2) : 2860~2870

[journal] Pan Q / 2021 / Silibinin-albumin nanoparticles : characterization and biological evaluation against oxidative stress-stimulated neurotoxicity associated with Alzheimer’s disease / J Biomed Nanotechnol 17(6) : 1123~1130

[journal] Jeon SG / 2019 / Vitamin D-binding proteinloaded PLGA nanoparticles suppress Alzheimer’s disease-related pathology in 5XFAD mice / Nanomed Nanotechnol Biol Med 17 : 297~307

[journal] Sánchez-López E / 2018 / Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease : in vitro and in vivo characterization / J Nanobiotechnol 16(1) : 32~

[journal] Tiwari SK / 2014 / Curcumin-loaded nanoparticles potently induce adult neurogenesis and reverse cognitive deficits in Alzheimer’s disease model via canonical Wnt/β-catenin pathway / ACS Nano 8(1) : 76~103

[journal] Zhang Y / 2021 / Berberine-albumin nanoparticles : preparation, thermodynamic study and evaluation their protective effects against oxidative stress in primary neuronal cells as a model of alzheimer’s disease / J Biomed Nanotechnol 17(6) : 1088~1097

[journal] Balducci C / 2014 / Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer’s disease mouse models / J Neurosci 34(42) : 14022~14031

[journal] Sanati M / 2021 / PEGylated superparamagnetic iron oxide nanoparticles(SPIONs)ameliorate learning and memory deficit in a rat model of Alzheimer’s disease : potential participation of STIMs / Neurotoxicology 85 : 145~159

[journal] Yusuf M / 2013 / Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model / J Drug Target 21(3) : 300~311

[journal] Zhang W / 2022 / Drug delivery of memantine with carbon dots for Alzheimer’s disease : blood-brain barrier penetration and inhibition of tau aggregation / J Colloid Interf Sci 617 : 20~31

[journal] Damian Guerrero E / 2021 / Carbon quantum dots for treatment of amyloid disorders / ACS Appl Nano Mater 4(3) : 2423~2433

[journal] Wang S / 2020 / Nontoxic black phosphorus quantum dots inhibit insulin amyloid fibrillation at an ultralow concentration / Science 23(5) : 101044~

[journal] Li S / 2012 / Delivery of quantum dot-siRNA nanoplexes in SK-N-SH cells for BACE1 gene silencing and intracellular imaging / Mol Therapy Nucleic Acids 1(4) : e20~

[journal] Waiskopf N / 2011 / Quantum dot labeling of butyrylcholinesterase maintains substrate and inhibitor interactions and cell adherence features / ACS Chem Neurosci 2(3) : 141~150

[journal] Jha S / 2018 / Pharmaceutical potential of quantum dots / Artif Cells Nanomed Biotechnol 46(sup1) : 57~65

[journal] Dong Zihao / 2022 / Cerium-doped carbon quantum dots trigger mung bean seeds to help mitigate salt stress by increasing the degree of stomata opening / Carbon Letters / 한국탄소학회 32(7) : 1715~1727

[journal] Kwon Yeon Ju / 2022 / Graphite–graphene architecture for Zn-ion hybrid supercapacitor electrodes / Carbon Letters / 한국탄소학회 32(5) : 1307~1313

[journal] Abdelbasset Walid Kamal / 2022 / Comparison and evaluation of the performance of graphene-based biosensors / Carbon Letters / 한국탄소학회 32(4) : 927~951

[journal] Yang Man / 2022 / Solvothermal preparation of CeO2 nanoparticles–graphene nanocomposites as an electrochemical sensor for sensitive detecting pentachlorophenol / Carbon Letters / 한국탄소학회 32(5) : 1277~1285

[journal] S. Akash Prabhu / 2021 / Graphene quantum dots synthesis and energy application: a review / Carbon Letters / 한국탄소학회 31(1) : 1~12

[journal] Umapathi R / 2021 / Colorimetric based on-site sensing strategies for the rapid detection of pesticides in agricultural foods : new horizons, perspectives, and challenges / Coord Chem Rev 446 : 214061~

[journal] Umapathi R / 2022 / Advances in optical-sensing strategies for the on-site detection of pesticides in agricultural foods / Trends Food Sci Technol 119 : 69~89

[journal] Drbohlavova J / 2009 / Quantum dots-characterization, preparation and usage in biological systems / Int J Mol Sci 10(2) : 656~673

[journal] Mansur HS / 2010 / Quantum dots and nanocomposites / Wiley Interdiscip Rev Nanomed Nanobiotechnol 2(2) : 113~129

[journal] Drummen GP / 2010 / Quantum dots-from synthesis to applications in biomedicine and life sciences / Int J Mol Sci 11(1) : 154~163

[journal] Pleskova S / 2018 / Using of quantum dots in biology and medicine / Adv Exp Med Biol 1048 : 323~334

[journal] Palmieri V / 2016 / The future development of bacteria fighting medical devices : the role of graphene oxide / Expert Rev Med Dev 13(11) : 1013~1019

[journal] Kalluri A / 2018 / Graphene quantum dots : synthesis and applications / Methods Enzymol 609 : 335~354

[journal] Palmieri V / 2018 / Graphene oxide coatings prevent Candida albicans biofilm formation with a controlled release of curcumin-loaded nanocomposites / Nanomedicine (Lond) 13(22) : 2867~2879

[journal] Palmieri V / 2019 / Graphene oxide touches blood : in vivo interactions of bio-coronated 2D materials / Nanoscale Horizons 4(2) : 273~290

[journal] Palmieri V / 2019 / Biocompatible N-acetyl cysteine reduces graphene oxide and persists at the surface as a green radical scavenger / Chem Commun (Camb) 55(29) : 4186~4189

[journal] Bruchez M Jr / 1998 / Semiconductor nanocrystals as fluorescent biological labels / Science 281(5385) : 2013~2016

[journal] Yan X / 2016 / Graphene quantum dot-MnO2 nanosheet based optical sensing platform: a sensitive fluorescence “turn off-on” nanosensor for glutathione detection and intracellular imaging / ACS Appl Mater Interfaces 8(34) : 21990~21996

[journal] Ananthanarayanan A / 2015 / Nitrogen and phosphorus co-doped graphene quantum dots : synthesis from adenosine triphosphate, optical properties, and cellular imaging / Nanoscale 7(17) : 8159~8165

[journal] Hardy J / 2002 / The amyloid hypothesis of Alzheimer’s disease : progress and problems on the road to therapeutics / Science 297(5580) : 353~356

[journal] Lansbury PT / 2006 / A century-old debate on protein aggregation and neurodegeneration enters the clinic / Nature 443(7113) : 774~779

[journal] Yamin G / 2008 / Amyloid beta-protein assembly as a therapeutic target of Alzheimer’s disease / Curr Pharm Des 14(30) : 3231~3246

[journal] Liu Y / 2018 / Synergistic inhibitory effect of GQDS-tramiprosate covalent binding on amyloid aggregation / ACS Chem Neurosci 9(4) : 817~823

[journal] Yan Y / 2019 / Recent advances on graphene quantum dots : from chemistry and physics to applications / Adv Mater 31(21) : e1808283~

[journal] Kim D / 2018 / Graphene quantum dots prevent α-synucleinopathy in Parkinson’s disease / Nat Nanotechnol 13(9) : 812~818

[journal] Tang H / 2021 / Graphene quantum dots obstruct the membrane axis of Alzheimer’s amyloid beta / Phys Chem Chem Phys 24(1) : 86~97

[journal] Liu Y / 2015 / Graphene quantum dots for the inhibition of β amyloid aggregation / Nanoscale 7(45) : 19060~19065

[journal] Zhu S / 2011 / Strongly green-photoluminescent graphene quantum dots for bioimaging applications / Chem Commun (Camb) 47(24) : 6858~6860

[journal] Liu C / 2019 / Modulation of β-amyloid aggregation by graphene quantum dots / R Soc Open Sci 6(6) : 190271~

[journal] Xiao S / 2016 / Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability / Biomaterials 106 : 98~110

[journal] Nilsberth C / 2001 / The “Arctic” APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation / Nat Neurosci 4(9) : 887~893

[journal] Zhou Y / 2016 / Detection of Aβ monomers and oligomers : early diagnosis of Alzheimer’s disease / Chem Asian J 11(6) : 805~817

[journal] Huang H / 2017 / Graphene quantum dots for detecting monomeric amyloid peptides / Nanoscale 9(16) : 5044~5048

[journal] Derfus AM / 2004 / Probing the cytotoxicity of semiconductor quantum dots / Nano Lett 4(1) : 11~18

[journal] Li D / 2022 / Prospects of NIR fluorescent nanosensors for green detection of SARS-CoV-2 / Sensors Actuators B Chem 362 : 131764~

[journal] Yang Y / 2015 / Hepatotoxicity assessment of Mn-doped ZnS quantum dots after repeated administration in mice / Int J Nanomed 10 : 5787~5796

[journal] Roberts JR / 2013 / Lung toxicity and biodistribution of Cd/Se-ZnS quantum dots with different surface functional groups after pulmonary exposure in rats / Part Fibre Toxicol 10 : 5~

[journal] Chan WC / 2002 / Luminescent quantum dots for multiplexed biological detection and imaging / Curr Opin Biotechnol 13(1) : 40~46

[journal] Limaye DA / 1999 / Cytotoxicity of cadmium and characteristics of its transport in cardiomyocytes / Toxicol Appl Pharmacol 154(1) : 59~66

[journal] Zhou Y / 2018 / The in vivo targeted molecular imaging of fluorescent silicon nanoparticles in Caenorhabditis elegans / Nano Res 11 : 2336~2346

[journal] Chang X / 2021 / Neurotoxicity of metal-containing nanoparticles and implications in glial cells / J Appl Toxicol JAT 41(1) : 65~81

[journal] Kang J / 2021 / Applications of nanotechnology in virus detection, tracking, and infection mechanisms / Nanomed Nanobiotechnol 13(4) : e1700~

KJCKorea
Journal Central

Carbon Letters 2023 KCI Impact Factor : 1.35 KCI-WoS Impact Factor : 6.04

Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer’s disease

ABSTRACT

KEYWORDS

Citation status

This is the result of checking the information with the same ISSN, publication year, volume, and start page between the WoS and the KCI journals. (as of 2024-07-26)

Total Citation Counts(KCI+WOS) (24) This is the number of times that the duplicate count has been removed by comparing the citation list of WoS and KCI.

Scopus Citation Counts (36) This is the result of checking the information with the same ISSN, publication year, volume, and start page between articles in KCI and the SCOPUS journals. (as of 2024-10-01)

* References for papers published after 2023 are currently being built.

Carbon Letters 2023 KCI Impact Factor : 1.35 KCI-WoS Impact Factor : 6.04

Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer’s disease

ABSTRACT

KEYWORDS

Statistics

Tools

Issue List

Citation status

KCI Citation Counts (2)

WoS Citation Counts (22) This is the result of checking the information with the same ISSN, publication year, volume, and start page between the WoS and the KCI journals. (as of 2024-07-26)

Total Citation Counts(KCI+WOS) (24) This is the number of times that the duplicate count has been removed by comparing the citation list of WoS and KCI.

Scopus Citation Counts (36) This is the result of checking the information with the same ISSN, publication year, volume, and start page between articles in KCI and the SCOPUS journals. (as of 2024-10-01)

REFERENCES (122) * References for papers published after 2023 are currently being built.

Search PDF

Citation

This is the result of checking the information with the same ISSN, publication year, volume, and start page between the WoS and the KCI journals. (as of 2024-07-26)

* References for papers published after 2023 are currently being built.